Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients.

Subjects

Subjects :

Antilymphocyte Serum therapeutic use
Antiviral Agents adverse effects
Azathioprine therapeutic use
Costs and Cost Analysis
Cyclosporine therapeutic use
Cytomegalovirus Infections economics
Follow-Up Studies
Ganciclovir adverse effects
Graft Rejection epidemiology
Humans
Immunosuppressive Agents therapeutic use
Morbidity
Prednisone therapeutic use
Sensitivity and Specificity
United States
Viremia diagnosis
Viremia economics
Viremia epidemiology
Antiviral Agents therapeutic use
Cytomegalovirus isolation & purification
Cytomegalovirus Infections drug therapy
Cytomegalovirus Infections prevention & control
Ganciclovir therapeutic use
Kidney Transplantation economics
Polymerase Chain Reaction methods
Postoperative Complications

Details

Language :

English

ISSN :

0041-1345

Volume :

29

Issue :

1-2

Database :

MEDLINE

Journal :

Transplantation proceedings

Publication Type :

Academic Journal

Accession number :

9123536

Full Text :

https://doi.org/10.1016/s0041-1345(96)00143-1